Unicycive Therapeutics Inc (NASDAQ:UNCY) has a beta value of 2.15 and has seen 2.02 million shares traded in the recent trading session. The company, currently valued at $66.42M, closed the recent trade at $0.64 per share which meant it gained $0.07 on the day or 11.31% during that session. The UNCY stock price is -150.0% off its 52-week high price of $1.60 and 68.75% above the 52-week low of $0.20. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.07 million shares traded. The 3-month trading volume is 977.13K shares.
The consensus among analysts is that Unicycive Therapeutics Inc (UNCY) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.07.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Sporting 11.31% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the UNCY stock price touched $0.64 or saw a rise of 1.54%. Year-to-date, Unicycive Therapeutics Inc shares have moved -19.43%, while the 5-day performance has seen it change 0.68%. Over the past 30 days, the shares of Unicycive Therapeutics Inc (NASDAQ:UNCY) have changed 22.96%. Short interest in the company has seen 1.52 million shares shorted with days to cover at 1.93.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
The company’s shares have gained 53.53% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -31.80% over the past 5 years.
UNCY Dividends
Unicycive Therapeutics Inc is expected to release its next earnings report on 2025-Mar-30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Insiders own 6.12% of the company shares, while shares held by institutions stand at 60.39% with a share float percentage of 64.33%. Investors are also buoyed by the number of investors in a company, with Unicycive Therapeutics Inc having a total of 33.0 institutions that hold shares in the company. The top two institutional holders are VIVO CAPITAL, LLC with over 3.47 million shares worth more than $1.74 million. As of 2024-06-30, VIVO CAPITAL, LLC held 9.9395% of shares outstanding.
The other major institutional holder is LOGOS GLOBAL MANAGEMENT LP, with the holding of over 3.47 million shares as of 2024-06-30. The firm’s total holdings are worth over $1.74 million and represent 9.9389% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 0.74% shares in the company for having 765.0 shares of worth $0.48 million while later fund manager owns 373.22 shares of worth $0.23 million as of Dec 31, 2024, which makes it owner of about 0.36% of company’s outstanding stock.
